Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$51.20 USD

51.20
2,122,230

+0.77 (1.53%)

Updated Jul 24, 2024 04:00 PM ET

Pre-Market: $52.70 +1.50 (2.93%) 8:48 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (201 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Anindya Barman headshot

5 Value Stocks With Exciting EV-to-EBITDA Ratios to Own Now

We have screened value stocks NMM, HPE, AEG, COWN and SNY based on the EV-to-EBITDA ratio, which offers a clearer picture of valuation and earnings potential.

Gilead (GILD) to Report Q4 Earnings: What's in the Cards?

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its fourth-quarter 2022 results.

Novartis' (NVS) Unit to Acquire Astellas' Rights of Mycamine

Novartis' (NVS) generic unit Sandoz is set to acquire rights to the antifungal product Mycamine from Astellas.

J&J (JNJ) Q4 Earnings Beat, Sales Miss, 2023 EPS View Upbeat

J&J (JNJ) beats estimates for fourth-quarter earnings but misses the same for sales. Its EPS outlook for 2023 is above expectations while sales fall short.

Sanofi (SNY) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Sanofi (SNY) closed at $48.63, marking a -0.92% move from the previous day.

Lilly (LLY) Jardiance Kidney Disease sNDA Gets FDA Acceptance

Eli Lilly's (LLY) sNDA seeks approval for diabetes medicine, Jardiance, to reduce the risk of kidney disease progression and cardiovascular death in adults with CKD.

The Zacks Analyst Blog Highlights PepsiCo, Verizon Communications, Sanofi, Vale and Paychex

PepsiCo, Verizon Communications, Sanofi, Vale and Paychex are part of the Zacks top Analyst Blog.

J&J (JNJ) to Begin Q4 Earnings Season for Pharma Sector

Growth in J&J's (JNJ) Pharma unit is expected to have been driven by drugs like Darzalex and Stelara. In the MedTech segment, continued recovery in worldwide procedure volume should drive sales.

Sheraz Mian headshot

Top Research Reports for PepsiCo, Verizon Communications & Sanofi

Today's Research Daily features new research reports on 16 major stocks, including PepsiCo, Inc. (PEP), Verizon Communications Inc. (VZ) and The Sanofi (SNY).

J&J (JNJ) Discontinues HIV Vaccine Phase III Mosaico Study

J&J (JNJ) discontinues phase III study on its investigational HIV vaccine regimen, which shows that the candidate lacks efficacy in preventing HIV.

Sanofi (SNY) Gains As Market Dips: What You Should Know

Sanofi (SNY) closed the most recent trading day at $49.83, moving +1.14% from the previous trading session.

Encompass Health's (EHC) Plan Marks Entry in Rhode Island

Encompass Health (EHC) aims to build a 50-bed inpatient rehabilitation hospital in Rhode Island and extend its advanced rehabilitative services suite across the Northeast.

SNY vs. NVO: Which Stock Is the Better Value Option?

SNY vs. NVO: Which Stock Is the Better Value Option?

State of California Sues Insulin Makers for Unfair Practices

The lawsuit aims to curb the skyrocketing cost of insulin charged by insulin manufacturers and pharmacy benefit managers companies. The State also seeks to recover some monetary compensation.

Aprea (APRE) Rises on Advancing Lead Drug to Clinical Studies

Aprea Therapeutics (APRE) advances its novel macrocyclic ATR inhibitor into early-stage clinical studies for treating advanced solid tumors.

Amarin's (AMRN) Q4 Preliminary Revenues Top Expectations

Amarin Corporation (AMRN) expects to generate total revenues in the range of $88-$90 million in fourth-quarter 2022. Share price rises following the announcement.

Regeneron (REGN) Down on Ophthalmology Drug Eylea Sales Update

Regeneron's (REGN) lead drug Eylea's sales decline in the fourth quarter due to a short-term shift to off-label use of Avastin.

AstraZeneca (AZN) Set to Acquire CinCor Pharma for $1.3B

AstraZeneca's (AZN) CinCor Pharma buyout is going to add blood pressure drug baxdrostat to its cardiorenal pipeline.

Sanofi (SNY) Gains As Market Dips: What You Should Know

Sanofi (SNY) closed the most recent trading day at $48.51, moving +0.77% from the previous trading session.

FDA Accepts Pfizer's (PFE) sBLA Filing for Pneumococcal Jab

The FDA grants priority review to Pfizer's (PFE) filing seeking label expansion of its pneumococcal 20-valent conjugate vaccine in infants and children. A decision is expected by this April.

Signet Jewelers and America's Car-Mart have been highlighted as Zacks Bull and Bear of the Day

Signet Jewelers and America's Car-Mart have been highlighted as Zacks Bull and Bear of the Day.

FDA Accepts AstraZeneca (AZN), Sanofi's RSV Antibody BLA

The FDA's decision on AstraZeneca (AZN)/Sanofi's (SNY) regulatory filing, seeking approval for using their RSV antibody in all infants, is expected in third-quarter 2023.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

What's in Store for Regeneron Pharmaceuticals (REGN) in 2023?

Regeneron Pharmaceuticals (REGN) had a good run in 2022 and the momentum should continue in 2023 on the back of growth in Eylea and Dupixent.